Crystagen

Crystagen is sold as the immune-system bioregulator of the Khavinson catalogue. Evidence tier: minimal, and here that is close to literal. A PubMed search on the name returns a single record — a 2014 abstract in Uspekhi Gerontologii (Advances in Gerontology), catalogued with the language field "rus" (Chervyakova et al., Adv Gerontol 2014).

Two things make this page unusual. That lone abstract reports a partly negative finding for Crystagen. And no indexed publication states what the molecule actually is.

The 2014 study compared four short peptides in ageing rat spleen. Vilon and a peptide designated R-1 were credited with activating T-helper cells; Timogen activated B cells by lowering apoptosis and raising proliferation. Crystagen, in the authors' words, "also activates B-cells of the immune system; however, the peptide doesn't cause cell renewal in spleen as it ages" (Chervyakova et al., 2014). Of four compounds tested, it was the one that failed the study's own renewal endpoint. The abstract reports no concentrations, sample size, or statistical result.

The theory it sits inside — that peptides of two to seven residues reach the nucleus and modulate transcription — comes from a review by the group that markets the peptides (Khavinson et al., Molecules 2021), not from mechanistic work on Crystagen.

No regulator has approved Crystagen for anything and no immunology guideline mentions it. It is not an immunosuppressant, adjuvant, or immunodeficiency treatment; nothing published tests it against any of those uses. "Immune support" language has no trial behind it in any language PubMed indexes.

Unapproved substances remain capturable by the List's general provisions, so being unnamed is not the same as being permitted. Any athlete subject to testing needs a ruling from their own anti-doping authority.

Nothing is published on Crystagen's safety in humans or whole animals — the sole study is a tissue-level comparison that did not measure adverse outcomes.

The one hazard worth naming is category-specific: a compound promoted as altering B-cell behaviour has no characterised interaction profile with autoimmune disease, immunosuppressive therapy, or transplant medication, because no study has looked. Absence of reported harm in a literature this small carries almost no information.

There is no pharmacokinetic dataset: no half-life, route comparison, bioavailability figure, or species. The single study exposed tissue directly, so not even a rodent milligram-per-kilogram anchor exists.

Vendors commonly list Crystagen as the tripeptide Glu-Asp-Pro. A tripeptide with that sequence does appear in the group's published work — coded T-36, where it stimulated proliferation in organotypic skin cultures from young rats — but that paper never uses the name Crystagen (Voicekhovskaya et al., Bull Exp Biol Med 2012). Tying brand to sequence is a marketplace convention no indexed source confirms, so a buyer cannot check against the literature what a vial is supposed to contain.

Better-documented alternatives sit in the same immune niche: Thymalin and Vilon, the latter appearing in the very study where Crystagen underperformed.

One abstract, one journal, one language, one year, and a result unfavourable on its own terms. No English-language primary paper exists, no clinical trial is registered, and no laboratory outside the originating network has published on the compound at all.

More on Crystagen across this site:

• Crystagen benefits and areas of interest
• Crystagen side effects and safety context
• Crystagen dosing concepts (educational)
• Crystagen research and evidence overview

How many studies exist on Crystagen? One indexed record: a Russian-language abstract from 2014 comparing four peptides in ageing rat spleen.

What did that study find? That Crystagen activated B cells but did not produce cell renewal in the ageing spleen — the weakest outcome among the four peptides compared.

Do we know what Crystagen is made of? Not from the literature. Sellers quote Glu-Asp-Pro; no indexed paper attaches that sequence to the name.

Is it approved or in trials anywhere? Neither. No approval in any major jurisdiction and no registered clinical trial.